Healthcare / BiotechnologyASX
$0.11
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-2.4M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-157.3%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-2.3M · FCF $-2.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $180.00 |
| Net Income | $-2.3M | $-2.3M | $-3.4M | $-4.0M | $-4.3M |
| EBITDA | $-2.3M | $-2.3M | $-3.2M | $-3.3M | $-3.7M |
| EPS | -0.04 | -0.04 | -0.07 | -0.12 | — |
| Gross Margin | — | — | — | — | 100.0% |
| Operating Margin | — | — | — | — | -2113772.2% |
| Net Margin | — | — | — | — | -2379205.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | -1.70 | -2.72 |
| Current Ratio | 0.58 | 0.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.1M | $-2.1M | $-2.4M | $-4.5M | $-3.3M |
| Returns | |||||
| ROE | -157.3% | -157.3% | -97.9% | 113.0% | 151.7% |
| Valuation | |||||
| P/B | 3.94 | 3.94 | 5.99 | — | — |
| Growth & Yield | |||||
| EPS Growth | 44.4% | 44.4% | 39.9% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+144.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.04
Residual
+144.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.